Trial Tracker

Hillier, SL et al. “Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial.” DOI: 10.1097/AOG.0000000000002135

Fizazi, K et al. “Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.” DOI: 10.1056/NEJMoa1704174

McDonald, CM et al. “Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.” DOI: http://dx.doi.org/10.1016/S0140-6736(17)31611-2

Maio, M et al. “Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.” DOI: http://dx.doi.org/10.1016/S1470-2045(17)30446-1

Kil, J et al. “Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial.” DOI: http://dx.doi.org/10.1016/S0140-6736(17)31791-9

Kim, WS et al. “Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.” DOI: http://dx.doi.org/10.1016/S2352-3026(17)30120-5

Hudson, JI et al. “Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.” DOI: 10.1001/jamapsychiatry.2017.1889

Pollack, CV et al. “Idarucizumab for Dabigatran Reversal — Full Cohort Analysis.” DOI: 10.1056/NEJMoa1707278

Kantarjian, HM et al. “Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.” DOI: http://dx.doi.org/10.1016/S2352-3026(17)30103-5